novo nordisk ozempic - Search News

News

Novo Nordisk ousts CEO

MarketWatch on MSN · 21h

Novo Nordisk rode Ozempic’s success to becoming Europe’s top company. Now it’s faltering and its CEO is out.

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday.

Fox Business on MSN · 18h

Novo Nordisk CEO steps down as Wegovy maker faces increased competition

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Quartz on MSN · 20h

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company said Friday.

9h

Ozempic-Maker CEO Ousted Over Pharma Company’s Rocky Market Downturn

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

19hon MSN

Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its ...

17hon MSN

Ozempic Drugmaker’s CEO Pushed Out Amid Weight-Loss Market Challenges

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

2d

Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

2d

Ignore The Noise - Novo Nordisk Is A Clear Buy

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Indianapolis Business Journal2d

Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results